Scandion Oncology A/S (SCOL.ST)
SEK 0.01
(-14.67%)
SEK 0.01
(-14.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 45.35 Million DKK | -43.42% |
| 2022 | 80.16 Million DKK | 44.79% |
| 2021 | 55.36 Million DKK | 141.9% |
| 2020 | 22.88 Million DKK | 48.63% |
| 2019 | 15.39 Million DKK | 503.98% |
| 2018 | 2.54 Million DKK | 592.16% |
| 2017 | 368.35 Thousand DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.09 Million DKK | -12.85% |
| 2024 Q2 | 9.35 Million DKK | -7.33% |
| 2023 Q4 | 11.58 Million DKK | 6.21% |
| 2023 Q2 | 11.31 Million DKK | -5.48% |
| 2023 FY | 44.79 Million DKK | -44.12% |
| 2023 Q1 | 11.97 Million DKK | -22.19% |
| 2023 Q3 | 10.91 Million DKK | -3.6% |
| 2022 Q2 | 24.84 Million DKK | 52.28% |
| 2022 Q4 | 15.38 Million DKK | -34.87% |
| 2022 FY | 80.16 Million DKK | 44.79% |
| 2022 Q1 | 16.31 Million DKK | 9.85% |
| 2022 Q3 | 23.62 Million DKK | -4.89% |
| 2021 Q1 | 9.81 Million DKK | 6.89% |
| 2021 FY | 55.36 Million DKK | 141.9% |
| 2021 Q4 | 14.84 Million DKK | -2.99% |
| 2021 Q3 | 15.3 Million DKK | -0.61% |
| 2021 Q2 | 15.4 Million DKK | 56.95% |
| 2020 Q2 | 4.75 Million DKK | 17.6% |
| 2020 Q1 | 4.04 Million DKK | -67.37% |
| 2020 Q4 | 9.17 Million DKK | 86.9% |
| 2020 FY | 22.88 Million DKK | 48.63% |
| 2020 Q3 | 4.91 Million DKK | 3.31% |
| 2019 Q4 | 12.39 Million DKK | 1073.6% |
| 2019 FY | 15.39 Million DKK | 503.98% |
| 2019 Q3 | 1.05 Million DKK | -4.89% |
| 2019 Q2 | 1.11 Million DKK | 31.76% |
| 2019 Q1 | 842.42 Thousand DKK | -62.14% |
| 2018 Q2 | 221.45 Thousand DKK | 243.69% |
| 2018 Q4 | 2.22 Million DKK | 5673.01% |
| 2018 FY | 2.54 Million DKK | 592.16% |
| 2018 Q1 | 64.43 Thousand DKK | -62.15% |
| 2018 Q3 | 38.54 Thousand DKK | -82.59% |
| 2017 Q3 | 75.25 Thousand DKK | 0.0% |
| 2017 FY | 368.35 Thousand DKK | 0.0% |
| 2017 Q4 | 170.21 Thousand DKK | 126.2% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Active Biotech AB (publ) | 44.8 Million SEK | -1.223% |
| Biovica International AB (publ) | 133.72 Million SEK | 66.081% |
| Cantargia AB (publ) | 290.01 Million SEK | 84.361% |
| CombiGene AB (publ) | 44.14 Million SEK | -2.748% |
| Cyxone AB (publ) | 28.21 Million SEK | -60.761% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -208.551% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -60.123% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 58.528% |
| Fluicell AB (publ) | 28.61 Million SEK | -58.497% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 66.326% |
| Mendus AB (publ) | 129.13 Million SEK | 64.877% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -524.064% |
| I-Tech AB | 40.14 Million SEK | -12.974% |
| Intervacc AB (publ) | 79.78 Million SEK | 43.151% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -525.269% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 66.628% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -176.55% |
| OncoZenge AB (publ) | 15.9 Million SEK | -185.174% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -6.392% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 87.317% |
| Lipum AB (publ) | 37.3 Million SEK | -21.578% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 85.23% |
| Ziccum AB (publ) | 27.87 Million SEK | -62.698% |
| BioArctic AB (publ) | 89.62 Million SEK | 49.394% |
| Genovis AB (publ.) | 88.19 Million SEK | 48.573% |
| Camurus AB (publ) | 1.05 Billion SEK | 95.72% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 21.84% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 45.464% |
| Aptahem AB (publ) | 10.01 Million SEK | -352.984% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 85.892% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 75.042% |
| Kancera AB (publ) | 63.07 Million SEK | 28.093% |
| Saniona AB (publ) | 1.07 Million SEK | -4111.421% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -129.192% |
| AcouSort AB (publ) | 25.87 Million SEK | -75.286% |
| Xintela AB (publ) | 57.31 Million SEK | 20.865% |
| Abliva AB (publ) | 27.86 Million SEK | -62.768% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -721.834% |
| Amniotics AB (publ) | 29.07 Million SEK | -56.016% |
| 2cureX AB (publ) | 36.51 Million SEK | -24.205% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -209.541% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.005% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 94.723% |
| Biosergen AB | 26.8 Million SEK | -69.186% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -156.501% |
| Corline Biomedical AB | 30.16 Million SEK | -50.348% |
| NextCell Pharma AB | -576.01 Thousand SEK | 7974.219% |
| Nanologica AB (publ) | 69.88 Million SEK | 35.1% |
| LIDDS AB (publ) | 27.75 Million SEK | -63.437% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 76.56% |
| BioInvent International AB (publ) | 441.4 Million SEK | 89.724% |
| SynAct Pharma AB | 224.49 Million SEK | 79.796% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -2.673% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -89.348% |
| Alzinova AB (publ) | 36.39 Million SEK | -24.621% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 59.106% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 84.346% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -477.335% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 60.584% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -107.157% |
| Simris Alg AB (publ) | 38.64 Million SEK | -17.377% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 68.279% |